GpIIb/IIIa inhibitors

Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Retrieved on: 
Monday, June 29, 2020
Chemical compounds, Organic compounds, GpIIb/IIIa inhibitors, Psychology, Piperidines, Cangrelor, Nucleotides, Organochlorides, Thioethers, Tirofiban, Inferiority complex

The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%9.0% vs 34.1%22.5%; P

Key Points: 
  • The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%9.0% vs 34.1%22.5%; P
  • Complete results from this study were published on June 27, 2020 in Circulation, a peer-reviewed journal of the American Heart Association.
  • As of this time, neither AGGRASTATnor any of the GP IIb/IIIa inhibitors are indicated for the use in STEMI patients.
  • Cangrelor, Tirofiban and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial.Circulation.

Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

Retrieved on: 
Tuesday, December 17, 2019
GpIIb/IIIa inhibitors, Chemical compounds, Organic compounds, Piperidines, Sulfonamides, Tirofiban, Eptifibatide, Percutaneous coronary intervention, AGG, Cardiology, Glycoprotein IIb/IIIa inhibitors

WINNIPEG, Dec. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT (tirofiban hydrochloride) injection versus Integrilin (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.

Key Points: 
  • WINNIPEG, Dec. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT (tirofiban hydrochloride) injection versus Integrilin (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.
  • Topline results of the SAVI-PCI trial will be communicated in a subsequent press release in Q1 of 2020.
  • The study reflects our investment in the Aggrastat brand, and our partnership with leading cardiologists across the United States, providing clinical data involving Aggrastat that reflects contemporary practice", said Albert Friesen, PhD, CEO of Medicure.
  • AGGRASTAT can cause serious bleeding.Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization.

Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Retrieved on: 
Thursday, December 12, 2019
GpIIb/IIIa inhibitors, Piperidines, Sulfonamides, Tirofiban, Cardiac catheterization, AGG

Medicure is proud to support innovative and contemporary clinical research involving Aggrastat, in particular sponsoring leading cardiologists such as Dr. Marco Valgimigli", said Albert Friesen, PhD, CEO of Medicure.

Key Points: 
  • Medicure is proud to support innovative and contemporary clinical research involving Aggrastat, in particular sponsoring leading cardiologists such as Dr. Marco Valgimigli", said Albert Friesen, PhD, CEO of Medicure.
  • Please note that the use of Aggrastat in STEMI patients has not been approved by the FDA.
  • As of this time, neither Aggrastat nor any of the GP IIb/IIIa inhibitors are indicated for the use in STEMI patients.
  • AGGRASTAT can cause serious bleeding.Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization.

Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study

Retrieved on: 
Wednesday, September 5, 2018
GpIIb/IIIa inhibitors, Piperidines, Sulfonamides, Tirofiban, Chemistry, Serious adverse event

Treatment with Brinavess also showed a median time to conversion of 11 minutes from start of first infusion among patients who converted.

Key Points: 
  • Treatment with Brinavess also showed a median time to conversion of 11 minutes from start of first infusion among patients who converted.
  • Twenty-eight (28) serious adverse events (SAEs) were reported for 26 patients and no deaths were reported in the study.
  • "This large European registry provides important data on the safety, efficacy and use of Brinavess in 1,778 patients in a real-world setting," said Kiran Bhirangi, M.D., Correvio's Vice President, Clinical Development and Medical Affairs.
  • Correvio and the Correvio Logo are the proprietary trademarks of Correvio Pharma Corp.
    Aggrastat and Brinavess are trademarks owned by Correvio and its affiliates worldwide.